Publication: 3702

Publication: 3702

Phase I/randomized phase II trial of TRC105 plus bevacizumab versus bevacizumab in recurrent glioblastoma: North Central Cancer Treatment Group N1174 (Alliance)

PubMed

PMC

QxMD

DOI

Google Scholar

Citation:: Neurooncol Adv vol 4 (1)

Year:: 2022
Type:: Manuscript
Funding:: NCTN
Endpoint:: Primary
Analysis:: Primary
Data Sharing:: No-Data-Sharing
Status:: Presented/Published
Citation Status:: Received

Note:

Methodological:: No
Biospecimen:: No
SDC:: No
Book Volume:: 11

Parents:: 2662
Children:: None

Program:: OGC
Primary Committee:: Neuro-Onc
Sec. Committees:: Health Outcomes

Pharmas:
Grants:: UG1CA189823, U10CA180821, U10CA180882, UG1CA233180, UG1CA233290, and U10CA180833

Corr. Author:
Authors:: Evanthia Galanis S Keith Anderson Erin Twohy Nicholas A Butowski Adilia Hormigo David Schiff Antonio Omuro Kurt A Jaeckle Shaji Kumar Timothy J Kaufmann Susan Geyer Priya U Kumthekar Jian Campian Caterina Giannini Jan C Buckner Patrick Y Wen

Networks:: CA824, FL028, LAPS-IL036, LAPS-MA036, LAPS-MN026, MONTEFIORE, VA009

Study: NCCTG-N1174
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:: 1/2

Keywords:: bevacizumab, CD105, glioblastoma, TRC105, angiogenesis